Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine

Sequential case-control studies were used to monitor changes in the clinical protection induced by group A meningococcal polysaccharide vaccine over a 3-year period. Overall, vaccine efficacy declined from 87% 1 year after vaccination to 70% and 54% at 2 and 3 years, respectively. When stratified by...

Full description

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 2; no. 8447; p. 114
Main Authors Reingold, A L, Broome, C V, Hightower, A W, Ajello, G W, Bolan, G A, Adamsbaum, C, Jones, E E, Phillips, C, Tiendrebeogo, H, Yada, A
Format Journal Article
LanguageEnglish
Published England 20.07.1985
Subjects
Adolescent
Age Factors
Bacterial Vaccines
Child
Child, Preschool
Female
Humans
Infant
Male
Meningitis, Meningococcal - epidemiology
Meningitis, Meningococcal - prevention & control
Meningococcal Vaccines
Polysaccharides, Bacterial - immunology
Vaccination
Online AccessGet more information

Cover

More Information
Summary:Sequential case-control studies were used to monitor changes in the clinical protection induced by group A meningococcal polysaccharide vaccine over a 3-year period. Overall, vaccine efficacy declined from 87% 1 year after vaccination to 70% and 54% at 2 and 3 years, respectively. When stratified by age at time of vaccination the data showed that, although vaccine efficacy remained high in children greater than or equal to 4 years of age (vaccine efficacy 85%, 74%, and 67% at 1, 2, and 3 years after vaccination, respectively), it declined dramatically in those less than 4 years of age at time of vaccination (vaccine efficacy 100%, 52%, and 8%, respectively, at 1, 2, and 3 years after vaccination). Thus, a single dose of group A meningococcal vaccine does not yield lasting clinical protection in children less than 4 years of age.
ISSN:0140-6736